stockrow
Friday 6 November 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
132.13
2.33
+1.80%
Follow AXSM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
14.23 | 12.22 | 16.33 | 11.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(487.10) | (418.04) | (384.77) | (1,021.26) | |
P/B ratio |
102.90 | 158.53 | 152.20 | 91.72 | |
Price to Tangible BV |
254.26 | 2,405.15 | 373.97 | 167.77 | |
EV/Sales |
13.92 | 11.96 | 16.08 | 10.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(95.13) | (119.79) | (175.23) | (115.98) | |
EV/FCF |
(94.64) | (119.35) | (173.53) | (114.80) | |
Quick Ratio |
1.44 | 1.27 | 1.30 | 1.29 | |
Current Ratio |
1.55 | 1.39 | 1.43 | 1.42 | |
Net Debt/EBITDA |
8.20 | 2.98 | 4.14 | 23.79 | |
Debt/Assets |
17.68% | 17.33% | 16.68% | 15.39% | |
Debt/Equity |
1.38 | 2.27 | 1.52 | 1.21 | |
Asset Turnover |
1.01 | 1.08 | 1.11 | 1.16 | |
Operating CF/Net income |
0.65 | 0.32 | 0.64 | 0.74 | |
Capex/Depreciation |
(0.03) | (0.05) | (0.15) | (0.06) | |
Interest Coverage |
(23.00) | (53.47) | (32.24) | (6.43) | |
Research and Development Expense of Revenue |
24.89% | 27.55% | 21.17% | 19.49% | |
Selling, General and Administrative Expense of Revenue |
86.38% | 96.75% | 95.31% | 78.21% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
11.60% | 12.26% | 12.43% | 10.15% | |
Graham Net Nets |
0.00 | (0.01) | 0.00 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.02%) | (2.21%) | (1.53%) | (1.66%) | |
Free Cash Flow Yield |
(1.03%) | (0.82%) | (0.57%) | (0.85%) | |
Revenue per Share |
3.94 | 3.73 | 4.22 | 4.95 | |
Operating CF per Share |
(0.37) | (0.40) | (0.64) | (0.18) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.41) | (0.64) | (0.18) | |
Cash per Share |
6.49 | 5.96 | 6.17 | 5.98 | |
Shareholders Equity per Share |
1.77 | 1.07 | 1.61 | 2.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.77 | 1.07 | 1.61 | 2.01 | |
Free Cash Flow |
(18.72) | (20.82) | (33.40) | (9.67) | |
Working Capital |
210.15 | 172.00 | 196.12 | 214.92 | |
Capital Expenditures |
(0.07) | (0.12) | (0.45) | (0.20) | |
Net Current Asset Value |
(12.52) | (47.81) | (21.57) | 3.30 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
183.23 | 206.23 | 238.14 | 269.81 | |
Average Payables |
68.77 | 96.18 | 85.30 | 75.15 | |
Average Inventory |
21.84 | 23.92 | 28.16 | 33.18 | |
Average Assets |
629.15 | 655.14 | 700.62 | 748.01 | |
Average Common Equity |
72.65 | 53.90 | 78.19 | 89.58 |
Columns are period end dates · fundamentals updated 6 Nov 2026